SG10202112057QA - Nuclease-mediated regulation of gene expression - Google Patents
Nuclease-mediated regulation of gene expressionInfo
- Publication number
- SG10202112057QA SG10202112057QA SG10202112057QA SG10202112057QA SG10202112057QA SG 10202112057Q A SG10202112057Q A SG 10202112057QA SG 10202112057Q A SG10202112057Q A SG 10202112057QA SG 10202112057Q A SG10202112057Q A SG 10202112057QA SG 10202112057Q A SG10202112057Q A SG 10202112057QA
- Authority
- SG
- Singapore
- Prior art keywords
- nuclease
- gene expression
- mediated regulation
- mediated
- regulation
- Prior art date
Links
- 101710163270 Nuclease Proteins 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000014493 regulation of gene expression Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562160396P | 2015-05-12 | 2015-05-12 | |
| US201662303595P | 2016-03-04 | 2016-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202112057QA true SG10202112057QA (en) | 2021-12-30 |
Family
ID=57249092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202112057QA SG10202112057QA (en) | 2015-05-12 | 2016-05-12 | Nuclease-mediated regulation of gene expression |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10808020B2 (en) |
| EP (1) | EP3294866A4 (en) |
| JP (2) | JP6873917B2 (en) |
| KR (1) | KR20170141217A (en) |
| AU (2) | AU2016261927B2 (en) |
| BR (1) | BR112017024115A2 (en) |
| CA (1) | CA2984013A1 (en) |
| CL (1) | CL2017002843A1 (en) |
| CO (1) | CO2017012026A2 (en) |
| HK (1) | HK1251011A1 (en) |
| IL (3) | IL284707B2 (en) |
| MX (2) | MX2017014446A (en) |
| PH (1) | PH12017502026A1 (en) |
| SA (1) | SA517390307B1 (en) |
| SG (1) | SG10202112057QA (en) |
| WO (1) | WO2016183298A2 (en) |
| ZA (1) | ZA201707016B (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3613852A3 (en) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| SI3068881T1 (en) * | 2013-11-13 | 2019-05-31 | Children's Medical Center Corporation | Nuclease-mediated regulation of gene expression |
| US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US10808020B2 (en) * | 2015-05-12 | 2020-10-20 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
| AU2016325613B2 (en) | 2015-09-23 | 2020-06-25 | Sangamo Therapeutics, Inc. | Htt repressors and uses thereof |
| JP7109784B2 (en) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Evolved Cas9 protein for gene editing |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| MX2019002207A (en) | 2016-08-24 | 2019-07-15 | Sangamo Therapeutics Inc | Regulation of gene expression using engineered nucleases. |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| SG11201901364VA (en) | 2016-08-24 | 2019-03-28 | Sangamo Therapeutics Inc | Engineered target specific nucleases |
| WO2018071868A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| TW201839136A (en) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | Compositions and methods for the treatment of hemoglobinopathies |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| KR20190127797A (en) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Cytosine to Guanine Base Editing Agent |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| CN111629747A (en) * | 2017-12-05 | 2020-09-04 | 沃泰克斯药物股份有限公司 | CRISPR-CAS9 modified CD34+ human pigment stem cells and progenitor cells and application thereof |
| EP3749767A1 (en) | 2018-02-05 | 2020-12-16 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
| US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
| AU2019326408A1 (en) | 2018-08-23 | 2021-03-11 | Sangamo Therapeutics, Inc. | Engineered target specific base editors |
| EP3908568A1 (en) | 2019-01-11 | 2021-11-17 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| MX2021011426A (en) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Methods and compositions for editing nucleotide sequences. |
| EP3946384A1 (en) | 2019-04-02 | 2022-02-09 | Sangamo Therapeutics, Inc. | Methods for the treatment of beta-thalassemia |
| IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| WO2022118310A1 (en) * | 2020-12-01 | 2022-06-09 | Lepton Pharmaceuticals Ltd. | Methods for enhancing therapeutic efficacy of isolated cells for cell therapy |
| AU2022343793A1 (en) | 2021-09-13 | 2024-03-14 | Life Technologies Corporation | Gene editing tools |
| WO2023081756A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
| WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2681922C (en) | 1994-01-18 | 2012-05-15 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| EP2022856B1 (en) | 1994-08-20 | 2011-09-14 | Gendaq Limited | Improvements in or relating to binding proteins for recognition of DNA |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
| EP1060261B1 (en) | 1998-03-02 | 2010-05-05 | Massachusetts Institute of Technology | Poly zinc finger proteins with improved linkers |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
| US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7030215B2 (en) * | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
| WO2001040798A2 (en) | 1999-12-06 | 2001-06-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
| WO2001059450A2 (en) | 2000-02-08 | 2001-08-16 | Sangamo Biosciences, Inc. | Cells expressing zinc finger protein for drug discovery |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| WO2001088197A2 (en) | 2000-05-16 | 2001-11-22 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
| JP2002060786A (en) | 2000-08-23 | 2002-02-26 | Kao Corp | Germicidal stainproofing agent for hard surface |
| US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
| US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
| US8106255B2 (en) | 2002-01-23 | 2012-01-31 | Dana Carroll | Targeted chromosomal mutagenasis using zinc finger nucleases |
| AU2003218382B2 (en) | 2002-03-21 | 2007-12-13 | Sangamo Therapeutics, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
| AU2003298574B2 (en) | 2002-09-05 | 2008-04-24 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| EP1732614B1 (en) | 2004-04-08 | 2008-12-24 | Sangamo Biosciences Inc. | Compositions for treating neuropathic and neurodegenerative conditions |
| CA2562193A1 (en) | 2004-04-08 | 2005-10-27 | Sangamo Biosciences, Inc. | Treatment of neuropathic pain with zinc finger proteins |
| AU2005287278B2 (en) | 2004-09-16 | 2011-08-04 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
| EP1877583A2 (en) | 2005-05-05 | 2008-01-16 | Arizona Board of Regents on behalf of the Unversity of Arizona | Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences |
| DE102005054628A1 (en) | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Process for the preparation of permanent human cell lines |
| CA2651494C (en) | 2006-05-25 | 2015-09-29 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
| EP2765195A1 (en) | 2006-05-25 | 2014-08-13 | Sangamo BioSciences, Inc. | Methods and compositions for gene inactivation |
| WO2008133938A2 (en) | 2007-04-26 | 2008-11-06 | Sangamo Biosciences, Inc. | Targeted integration into the ppp1r12c locus |
| ES2500515T3 (en) | 2007-06-19 | 2014-09-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogues of the messenger RNA cap |
| CA2700231C (en) | 2007-09-27 | 2018-09-18 | Sangamo Biosciences, Inc. | Rapid in vivo identification of biologically active nucleases |
| AU2009238629C1 (en) | 2008-04-14 | 2015-04-30 | Sangamo Therapeutics, Inc. | Linear donor constructs for targeted integration |
| CA2725773C (en) | 2008-05-28 | 2017-12-05 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
| US8703489B2 (en) | 2008-08-22 | 2014-04-22 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
| MX2011002731A (en) | 2008-09-15 | 2011-04-26 | Childrens Medical Center | Modulation of bcl11a for treatment of hemoglobinopathies. |
| EP3156494B8 (en) | 2008-12-04 | 2018-09-19 | Sangamo Therapeutics, Inc. | Genome editing in rats using zinc-finger nucleases |
| WO2011016840A2 (en) * | 2009-07-28 | 2011-02-10 | Sangamo Biosciences, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
| EP2459231B1 (en) | 2009-07-31 | 2016-06-08 | Ethris Gmbh | Rna with a combination of unmodified and modified nucleotides for protein expression |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| EP2615106B1 (en) | 2010-02-08 | 2018-04-25 | Sangamo Therapeutics, Inc. | Engineered cleavage half-domains |
| CA2788850C (en) | 2010-02-09 | 2019-06-25 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| US8771985B2 (en) | 2010-04-26 | 2014-07-08 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using zinc-finger nucleases |
| KR101974036B1 (en) | 2010-05-03 | 2019-04-30 | 상가모 테라퓨틱스, 인코포레이티드 | Compositions for linking zinc finger modules |
| CA2798988C (en) | 2010-05-17 | 2020-03-10 | Sangamo Biosciences, Inc. | Tal-effector (tale) dna-binding polypeptides and uses thereof |
| CA2805442C (en) | 2010-07-21 | 2020-05-12 | Sangamo Biosciences, Inc. | Methods and compositions for modification of an hla locus |
| WO2012094132A1 (en) | 2011-01-05 | 2012-07-12 | Sangamo Biosciences, Inc. | Methods and compositions for gene correction |
| WO2013044008A2 (en) | 2011-09-21 | 2013-03-28 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
| AU2012328682B2 (en) | 2011-10-27 | 2017-09-21 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of the HPRT locus |
| CA2854819C (en) | 2011-11-16 | 2022-07-19 | Sangamo Biosciences, Inc. | Modified dna-binding proteins and uses thereof |
| CA2868398A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| RU2650819C2 (en) | 2012-05-07 | 2018-04-17 | Сангамо Терапьютикс, Инк. | Methods and compositions for nuclease-mediated targeting of transgenes |
| BR122021002108B1 (en) * | 2012-05-28 | 2022-08-16 | Evogene Ltd | METHOD TO INCREASE PRODUCTION, GROWTH RATE, BIOMASS, VIGOR, SEED PRODUCTION, NITROGEN USE EFFICIENCY, AND/OR TOLERANCE TO ABIOTIC STRESS OF A PLANT, AND CONSTRUCTION OF ISOLATED NUCLEIC ACID |
| CN104704110B (en) * | 2012-08-29 | 2018-06-01 | 桑格摩生物科学股份有限公司 | For treating the method and composition of heredity symptom |
| SG11201504038XA (en) * | 2012-11-27 | 2015-06-29 | Childrens Medical Center | Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction |
| AU2013355327A1 (en) | 2012-12-05 | 2015-06-11 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of metabolic disorders |
| CA2910489A1 (en) | 2013-05-15 | 2014-11-20 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
| EP3988654A1 (en) | 2013-08-28 | 2022-04-27 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
| SI3068881T1 (en) * | 2013-11-13 | 2019-05-31 | Children's Medical Center Corporation | Nuclease-mediated regulation of gene expression |
| BR112016025849A2 (en) | 2014-05-08 | 2017-10-17 | Chdi Foundation Inc | methods and compositions for the treatment of huntington's disease |
| ES2835861T3 (en) | 2015-05-08 | 2021-06-23 | Childrens Medical Ct Corp | Targeting of functional regions of the BCL11A enhancer for fetal hemoglobin reinduction |
| US10808020B2 (en) * | 2015-05-12 | 2020-10-20 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
| CA3009727A1 (en) | 2015-12-28 | 2017-07-06 | Novartis Ag | Compositions and methods for the treatment of hemoglobinopathies |
| US20200330609A1 (en) | 2016-04-18 | 2020-10-22 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
-
2016
- 2016-05-12 US US15/565,811 patent/US10808020B2/en active Active
- 2016-05-12 SG SG10202112057QA patent/SG10202112057QA/en unknown
- 2016-05-12 MX MX2017014446A patent/MX2017014446A/en unknown
- 2016-05-12 AU AU2016261927A patent/AU2016261927B2/en active Active
- 2016-05-12 EP EP16793510.5A patent/EP3294866A4/en active Pending
- 2016-05-12 BR BR112017024115A patent/BR112017024115A2/en active Search and Examination
- 2016-05-12 WO PCT/US2016/032049 patent/WO2016183298A2/en active Application Filing
- 2016-05-12 JP JP2017559044A patent/JP6873917B2/en active Active
- 2016-05-12 IL IL284707A patent/IL284707B2/en unknown
- 2016-05-12 KR KR1020177032403A patent/KR20170141217A/en not_active Application Discontinuation
- 2016-05-12 CA CA2984013A patent/CA2984013A1/en active Pending
-
2017
- 2017-10-17 ZA ZA2017/07016A patent/ZA201707016B/en unknown
- 2017-10-26 IL IL255288A patent/IL255288B/en unknown
- 2017-11-07 PH PH12017502026A patent/PH12017502026A1/en unknown
- 2017-11-08 SA SA517390307A patent/SA517390307B1/en unknown
- 2017-11-09 CL CL2017002843A patent/CL2017002843A1/en unknown
- 2017-11-10 MX MX2021005226A patent/MX2021005226A/en unknown
- 2017-11-27 CO CONC2017/0012026A patent/CO2017012026A2/en unknown
-
2018
- 2018-08-13 HK HK18110341.5A patent/HK1251011A1/en unknown
-
2020
- 2020-09-15 US US17/021,555 patent/US20210024606A1/en not_active Abandoned
-
2021
- 2021-04-21 JP JP2021071881A patent/JP7365374B2/en active Active
- 2021-10-06 IL IL287033A patent/IL287033A/en unknown
-
2022
- 2022-07-06 AU AU2022204863A patent/AU2022204863A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016183298A2 (en) | 2016-11-17 |
| US20210024606A1 (en) | 2021-01-28 |
| ZA201707016B (en) | 2019-08-28 |
| SA517390307B1 (en) | 2021-07-13 |
| MX2021005226A (en) | 2021-06-18 |
| BR112017024115A2 (en) | 2018-08-07 |
| WO2016183298A3 (en) | 2016-12-29 |
| AU2016261927A1 (en) | 2017-11-02 |
| US10808020B2 (en) | 2020-10-20 |
| CA2984013A1 (en) | 2016-11-17 |
| AU2016261927B2 (en) | 2022-04-07 |
| EP3294866A2 (en) | 2018-03-21 |
| CO2017012026A2 (en) | 2018-02-28 |
| IL284707A (en) | 2021-08-31 |
| AU2022204863A1 (en) | 2022-07-28 |
| MX2017014446A (en) | 2018-06-13 |
| IL255288B (en) | 2021-10-31 |
| CL2017002843A1 (en) | 2018-05-25 |
| EP3294866A4 (en) | 2018-12-05 |
| KR20170141217A (en) | 2017-12-22 |
| IL287033A (en) | 2021-12-01 |
| JP7365374B2 (en) | 2023-10-19 |
| US20180111975A1 (en) | 2018-04-26 |
| HK1251011A1 (en) | 2019-01-18 |
| JP2021106611A (en) | 2021-07-29 |
| JP2018516556A (en) | 2018-06-28 |
| IL284707B1 (en) | 2023-09-01 |
| PH12017502026A1 (en) | 2018-04-02 |
| IL255288A0 (en) | 2017-12-31 |
| IL284707B2 (en) | 2024-01-01 |
| JP6873917B2 (en) | 2021-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287033A (en) | Nuclease-mediated regulation of gene expression | |
| IL284796A (en) | Regulation of gene expression by aptamer-mediated modulation of alternative splicing | |
| ZA201900765B (en) | Regulation of gene expression using engineered nucleases | |
| HUE044540T2 (en) | Nuclease-mediated regulation of gene expression | |
| IL255515A (en) | Identification of genetic modifications | |
| EP3118315A4 (en) | Nucleic acid that inhibits expression of irf5 | |
| ZA201804397B (en) | Biosynthetic gene cluster of carrimycin | |
| IL249254B (en) | Gene expression system | |
| HK1231403A1 (en) | Nucleic acid capable of inhibiting expression of beta2gpi 2gpi |